
|Videos|May 5, 2022
Other Investigational Agents Targeting BCL-2 Family Proteins for Multiple Myeloma Treatment
Author(s)Shaji Kumar, MD, Jonathan L. Kaufman, MD
Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. An explanation of the focus on BCL-2 inhibitors versus the development of MCL-1 inhibitors for multiple myeloma treatment.
Episodes in this series






















